NCT04704219 · FLOW

Participant flow

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) · Source last updated 2025-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
Participants with non-clear cell Renal Cell Carcinoma (nccRCC) received 400 mg Pembrolizumab (Pembro) intravenously (IV) on Day 1 of a 42-day cycle (every 6 weeks (Q6W)) for approximately 2 years PLUS 20 mg Lenvatinib (Lenva) orally once daily (QD) on Days 1 and 22 of a 42-day cycle (Q6W). Participants continued study intervention until progressive disease or discontinuation.
id
FG000
title
Pembrolizumab + Lenvatinib

periods

drop Withdraws
reasons
group Id
FG000
num Subjects
1
type
Screen Failure
reasons
group Id
FG000
num Subjects
1
type
Withdrawal by Subject
reasons
group Id
FG000
num Subjects
78
type
Death
reasons
group Id
FG000
num Subjects
80
type
Participants Ongoing
milestones
achievements
group Id
FG000
num Subjects
160
type
STARTED
achievements
group Id
FG000
num Subjects
158
type
Treated
achievements
group Id
FG000
num Subjects
6
type
Second Course Treatment
achievements
group Id
FG000
num Subjects
0
type
COMPLETED
achievements
group Id
FG000
num Subjects
160
type
NOT COMPLETED
title
Overall Study

pre Assignment Details

Per protocol, six participants who experienced progression of Renal Cell Carcinoma (RCC) by radiographic evaluation continued second course treatment.

recruitment Details

This study was conducted at 56 centers in 14 countries.

Complete source fields